



2017 MSK Cardio-Oncology Symposium

Cardiovascular Health and Disease During and After Cancer Therapy

A CASE-BASED CURRICULUM

Friday-Saturday, May 12-13, 2017

Memorial Sloan Kettering Cancer Center
Rockefeller Research Laboratories
430 East 67th Street
New York, NY 10065



Memorial Sloan Kettering
Cancer Center

2017 MSK Cardio-Oncology Symposium

Cardiovascular Health and Disease
During and After Cancer Therapy:

A CASE-BASED CURRICULUM

Over the past decade, the cardiovascular care of patients with cancer has evolved as a subspecialty driven by novel therapies that can cure or control patients, allowing many patients to be living long enough to experience the potential cardiotoxic effects of these treatments. The purpose of this conference is to provide a case-based curriculum that addresses important clinical topics relevant to the cardiovascular health of patients with cancer. Clinical experts from Memorial Sloan Kettering Cancer Center and around the country will present an up-to-date overview on the best practice strategies in the evaluation and management of heart disease in cancer patients from early diagnosis, treatment and long-term surveillance. All presentations will include devoted time to permit interaction between audience members and presenters.

LEARNING LAB

There will be a separate hands on, computer-based session on advanced echo imaging techniques of strain imaging and 3D quantification of left ventricular function in cardio-oncology.

Space limited to 50 participants.

TARGET AUDIENCE

This course is intended for cardiologists, internists, hematologists/oncologists and other affiliated healthcare professionals who are involved in the care of cancer patients or have a special interest in this area.

COURSE OBJECTIVES

By the end of this course, participants should be able to:

- State the commonly used cancer therapy regimens associated with cardiotoxicity including novel targeted therapies.
- Recognize the cardiovascular concerns with conventional and newer targeted therapy used to treat cancer and the timeline of cardiotoxicity manifestation.
- State specific examples of cardiovascular challenges during cancer therapy
- Illustrate the utility of preclinical biomarkers and imaging modalities for cardiotoxicity monitoring.
- Define the strengths and weaknesses of each imaging technique in the detection and prediction of cardiotoxicity.
- Describe primary and secondary prevention of cardiovascular disease in cancer patients during and after cancer therapy.
- Discuss the implementation of cardio-oncology practice guidelines to formulate best practice strategies.
- State the goals and principles of a multidisciplinary team in cardio-oncology and the approach to building a cardio-oncologic clinic.
- Evaluate the impact of cardio-oncology specialty care in the overall cardiovascular outcome of patients with cancer.

Join the Conversation!



#MSKCardioOncCME

Course Faculty

MSK COURSE DIRECTORS



Jennifer Liu, MD



Richard M. Steingart, MD

MSK FACULTY

Michael Baum, MD

Carol Chen, MD

Paul Cohen, MD, PhD

Chau Dang, MD

Dipti Gupta, MD, MPH

Michelle Johnson, MD, MPH

Eileen McAleer, MD

Nancy Roistacher, MD

Wendy Schaffer, MD, PhD

Jessica Scott, PhD

Gerald Soff, MD

Susan Slovin, MD, PhD

Howard Weinstein, MD

Anthony Yu, MD

INVITED FACULTY

Saro Armenian, DO

City of Hope Medical Center

Usman Baber, MD

Mt. Sinai Hospital

Ana Barac, MD, PhD

Washington Hospital

Ann Blaes, MD

University of Minnesota

Jim Cheung, MD

Weill Cornell Medical Center

Stephan Danik, MD

Mt. Sinai Beth Israel Hospital

Susan Dent, MD

University of Ottawa

Christopher Lau, MD

Weill Cornell Medical Center

Daniel Lenihan, MD

Vanderbilt University Medical Center

Steven Lipshultz, MD

Wayne State University

Javid Moslehi, MD

Vanderbilt University Medical Center

Ileana Pina, MD, MPH

Montefiore Hospital/Albert Einstein

Marielle Scherrer-Crosbie, MD, PhD

University of Pennsylvania

Jonathan Weinsaft, MD

Weill Cornell Medical Center

Scientific Agenda | May 12, 2017

7:00 am **REGISTRATION & BREAKFAST**

8:00 am **Department of Medicine Grand Rounds**
The Quest to Improve Chemotherapy
while Minimizing Cardiotoxicity
Steven Lipshultz, MD

9:00 am **Introduction & Overview**
Jennifer Liu, MD
Richard Steingart, MD

SESSION I **Defining Clinical Problems**

MODERATOR Michelle Johnson, MD, MPH

9:10 am **Heart Disease in Cancer Patients –**
Why Is It So Important Now?
Richard Steingart, MD

9:30 am **Optimizing Outcomes When Treating Breast Cancer**
with Cardiotoxic Therapies
Chau Dang, MD

9:50 am **Late Onset Cardiotoxicity in Adult Survivors of**
Childhood Cancer: Incidence, Risk Factors and Individual
CV Risk Prediction
Saro Armenian, DO

10:10 am **Cancer Therapy Induced Heart Failure:**
Do the Traditional Paradigms Apply?
Ileana Pina, MD, MPH

10:30 am **Panel Discussion & Questions**

10:50 am **BREAK & REFRESHMENTS**

SESSION II **Cardiotoxicity of Cancer Treatment**

MODERATOR Howard Weinstein, MD

11:10 am **Radiation Induced Cardiotoxicity – Why Worry?**
Dipti Gupta, MD, MPH

11:30 am **Understanding the Role of Androgen Deprivation Therapy in**
Prostate Cancer Including the Potential for Cardiac Toxicity
Susan Slovin, MD, PhD

11:50 am **Cardiotoxicity of Established and Emerging Cancer**
Drugs Beyond Adriamycin: Practical Tips on Management
Javid Moslehi, MD

12:10 pm **Panel Discussion & Questions**

12:30 pm **LUNCH**

Scientific Agenda | May 12, 2017

SESSION III

Evaluation and Management of Cardiovascular Disease During and After Cancer Therapy

MODERATOR Javid Moslehi, MD

- 1:30 pm **Trastuzumab and Cardiac Monitoring in Breast Cancer: Current Recommendations**
Anthony Yu, MD
- 1:50 pm **Challenges in the Management of LV Dysfunction, Arrhythmias, HTN and Ischemia During Cancer Therapy**
Carol Chen, MD
- 2:10 pm **Thrombosis in Cancer Patients: Prevention and Treatment**
Gerald Soff, MD
- 2:30 pm **How to Manage 5FU Induced Chest Pain Syndrome**
Wendy Schaffer, MD, PhD
- 2:50 pm **Amyloid, Carcinoid and Pheochromocytoma**
Jennifer Liu, MD
- 3:10 pm **Newest ASCO Cardio-Oncology Practice Guideline: Key Take Home Points**
Saro Armenian, DO
- 3:30 pm **Panel Discussion & Questions**
- 3:50 pm **BREAK & REFRESHMENTS**

SESSION IV

Imaging and Preclinical Markers for Cardiotoxicity Monitoring

MODERATOR Nancy Roistacher, MD

- 4:05 pm **Is 2D LVEF enough? The Role of Biomarker, Strain Imaging and 3D Echocardiography**
Marielle Scherrer-Crosbie, MD, PhD
- 4:25 pm **The EKG: QT Monitoring and Torsades During Cancer Treatment**
Stephen Danik, MD
- 4:45 pm **MRI in Cardio-Oncology: Evaluation of Cardiac Masses and Myocardial Disease**
Jonathan Weinsaft, MD
- 5:05 pm **Relevance of Nuclear Imaging to Cardio-Oncology**
Richard Steingart, MD
- 5:25 pm **I am a Clinician, Make it Simple: What Echo Thresholds Do I Choose for Therapeutic Interventions**
Jennifer Liu, MD
- 5:45 pm **Panel Discussion & Questions**
- 6:00 pm **ADJOURN**

Scientific Agenda | May 13, 2017

7:00 am **REGISTRATION & BREAKFAST**

7:55 am **Day II Welcome**
Jennifer Liu, MD
Richard Steingart, MD

8:00 am **Key Note Lecture**
**Cardio-Oncology: Past, Present and Future.
How to Make a Difference in Patient Care**
Dan Lenihan, MD

SESSION V Preventive Care in Cardio-Oncology

MODERATOR Michael Baum, MD

8:20 am **Common Risk Factors Between Cancer and
Cardiovascular Disease**
Ann Blaes, MD

8:40 am **Protective Role of Aerobic Exercise: Can it Mitigate
Cardiotoxicity and Improve Outcomes?**
Jessica Scott, PhD

9:00 am **Cardiometabolic Issues in Cardio-Oncology**
Paul Cohen, MD, PhD

9:20 am **Transitioning into Survivorship Care: the Role of the PCP**
Ann Blaes, MD

9:40 am **Panel Discussion & Questions**

10:00 am **BREAK & REFRESHMENTS**

SESSION VI Cardiovascular Interventional Subspecialties in Cancer Patients

MODERATOR Eileen McAleer, MD

10:20 am **Interventional Cardiologist: Medical and Interventional
Management of Acute and Chronic Coronary Artery Disease,
and TAVR in Cancer Patients**
Usman Baber, MD

10:40 am **CV Surgeon: Advanced Cardiac Procedures in Cancer Patients:
Bypass, Valve Replacement, TAVR, LVAD, Transplant**
Christopher Lau, MD

11:00 am **Electrophysiologist: Management of Arrhythmia During
and After Cancer Therapy**
Jim Cheung, MD

11:20 am **Panel Discussion & Questions**

SESSION VII Building the Team: The Cardio-Oncology Program

11:40 am **Establishing a Cardio-Oncologic Clinic**
Susan Dent, MD

12:00 pm **Cardio-Oncology Subspecialty: ACC Initiatives. How to Get Involved**
Ana Barac, MD, PhD

12:20 pm **Panel Discussion & Questions**

12:35 pm **Closing Remarks & Adjourn**
Jennifer Liu, MD

Advanced Echo Imaging Learning Lab (Optional)

2:00 pm **Computer Based, Hands-On Session on Strain and 3D EF Analysis**
Jennifer Liu, MD & Faculty

4:00 pm **ADJOURN**

REGISTRATION

	EARLY Before 3/12/17	GENERAL After 3/12/17
Physicians (MDs, PhDs & DOs)	\$325	\$375
Residents, Fellows & Other Healthcare Professionals	\$150	\$200
Industry Members*	\$650	\$650
Learning Lab (Optional Add-On)	\$100	\$100

Register online at:
www.mskcc.org/cardio-onc

Registration includes continental breakfast, lunch and refreshment breaks. Please contact us at least one week prior to the course if you have any special dietary needs.

- **30% Discounted Rate for MSK Alumni and MSK Alliance Members**
MSK offers a discounted rate to all MSK Alumni and MSK Alliance members to attend a CME course. Please contact cme@mskcc.org for more information or to register.
- **MSK Staff Registration**
Registration is complimentary for MSK staff who wish to attend this course. However, you must register online by visiting the course website, www.mskcc.org/cardio-onc.
- **Learning Lab (Optional Add-On)**
There will be a separate hands on, computer-based session on advanced echo imaging techniques of strain imaging and 3D quantification of ventricular function in cardio-oncology. Sign up online during course registration; **space is limited to 50 participants**.

ACCREDITATION STATEMENT

MSK is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA CREDIT DESIGNATION STATEMENT

MSK designates this live activity for a maximum of **14.25 AMA PRA Category 1 Credits™**. Physicians should only claim credit commensurate with the extent of their participation in the activity. The AMA has determined that physicians not licensed in the United States but who participate in this CME activity are eligible for **14.25 AMA PRA Category 1 Credits™**.

FACULTY DISCLOSURE

It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it sponsors as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity sponsored by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.

ACCOMMODATIONS

For travel information, including hotels in the area of MSK with discounted rates, please visit: www.mskcc.org/cme.

CONTACT

Continuing Medical Education
Memorial Sloan Kettering Cancer Center
633 Third Avenue, 12th Floor
New York, NY 10017
www.mskcc.org/cme
cme@mskcc.org

STAY CONNECTED

Stay connected with with #MSKCME

 /MSKCME

 @MSKCME

 MSK CME LinkedIn Group

*Industry Members: Registration is for educational purposes only. Marketing, sales, and promotion of products and services are prohibited at CME activities.